Enliven Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule inhibitors aimed at improving the lives of cancer patients. With a focus on precision oncology, Enliven seeks to address both existing and emerging unmet medical needs, enhancing survival and overall well-being through innovative therapies. The company combines deep insights into clinically validated biological targets with differentiated chemistry to design effective treatments. Operating in a fast-paced startup environment, Enliven emphasizes collaboration across various teams to advance oncology clinical trials and drive drug development.